

I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on 26 Aug. 2008

TOWNSEND and TOWNSEND and CREW LLP

By: Melinda Adogiti

PATENT
Attorney Docket No.: 027607-000212US
Customer No.: 20350

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ZAGHOUBANI, Habib

Application No.: 09/623,728

Filed: January 22, 2001

For: COMPOUNDS, COMPOSITIONS
AND METHODS FOR THE
ENDOCYTIC PRESENTATION OF
IMMUNOSUPPRESSIVE FACTORS

Customer No.: 20350

Confirmation No. 6688

Examiner: Szperka, Michael Edward

Art Unit: 1644

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the request to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed May 27, 2008, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing. Please amend the specification as follows.

Appl. No. 09/623,728
Amdt. dated August 25, 2008
Reply to Office Action of May 27, 2008

PATENT

Amendments to the Specification begin on page 3 of this paper.

Remarks begin on page 4 of this paper.